F tier · safety concern
Genuinely interesting rodent pharmacology with zero human trials, in a drug class whose best-known member has killed people — the combination of no human data and a lethal class precedent puts it at the bottom.
bam-15
BAM15 is a mitochondrial protonophore that has been reported to reverse diet-induced obesity and improve insulin sensitivity in mice without reducing food intake. There are no registered or published human trials, so the reported wider safety window relative to older uncouplers rests entirely on animal and cell data.
the explanation
This chemical makes mitochondria leak energy as heat instead of storing it, so mice burn more calories without eating less. It has never been tested in a human, and the older drug that works this way, DNP, has killed people by overheating them.
regulatory status
Not approved anywhere; no registered clinical trials
BAM15 is not approved as a drug in any jurisdiction and is not a lawful dietary supplement ingredient. A ClinicalTrials.gov query returned no studies of the mitochondrial uncoupler BAM15. Note separately that 2,4-dinitrophenol, the historical member of this drug class, is banned for human consumption in multiple jurisdictions.
how it works · proposed mechanism
BAM15 works by deliberately making mitochondria inefficient, so energy from food is released as heat rather than captured as ATP.
Proton gradient dissipation
As a protonophore, BAM15 shuttles protons back across the inner mitochondrial membrane, short-circuiting the gradient that drives ATP synthase. Substrate oxidation continues while ATP yield falls, and the difference leaves as heat.
Intake-independent energy expenditure
In mice, whole-body oxygen consumption rose roughly 15% during the dark cycle at the 0.1% diet concentration while food intake was identical to controls. Fat mass fell without the compensatory hyperphagia that limits many metabolic interventions.
Claimed wider therapeutic window
Unlike DNP, BAM15 was reported not to depolarise the plasma membrane and to sustain high respiration across a wider concentration range in cells. In mice, doses up to 200 mg/kg were reported to have no effect on body temperature — the failure mode that makes DNP lethal.
what’s reported
evidence shape
5 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
The animal data is legitimately strong for animal data, and the specific claim that BAM15 separates fat loss from hyperthermia is the reason anyone takes it seriously. But that separation has never been tested in a human, and the class it belongs to has a documented body count — a 2011 review counted 62 published deaths from 2,4-dinitrophenol, with no antidote and an average of about 14 hours from acute overdose to death.
key published findings
- Rodent: in C57BL/6J mice on a western diet, 0.10-0.15% w/w BAM15 completely prevented diet-induced fat mass gain over 8 days with unchanged food intake and unaffected lean mass (Alexopoulos et al., Nat Commun 2020;11:2397).
- Rodent: in an obesity-reversal arm, body weight was about 15% lower than western-diet controls, plasma triglycerides fell 29%, and dark-cycle whole-body oxygen consumption rose about 15% at 0.1% BAM15 — with identical caloric intake to controls (Nat Commun 2020;11:2397).
- Rodent: hyperinsulinaemic-euglycaemic clamp showed glucose infusion rate normalised toward chow-fed levels with improved skeletal muscle glucose uptake; in a separate group, BAM15 stimulated energy expenditure and improved glycemic control (Axelrod et al., EMBO Mol Med 2020;12:e12088).
- Rodent safety / in vitro: doses up to 200 mg/kg reportedly had no effect on body temperature, with ALT, AST, GLDH, creatine kinase and creatinine unaffected and blood urea nitrogen mildly elevated (22%) but within the stated reference range; in cells BAM15 was reported as approximately 7-fold more potent than DNP with a broader window, DNP inhibiting respiration above 30 µM while BAM15 maintained high respiration across 3-100 µM (Nat Commun 2020;11:2397).
- Human trial: none. A ClinicalTrials.gov query returned no registered studies of the mitochondrial uncoupler BAM15.
limitations of the evidence
- All efficacy and all safety-margin evidence is rodent or cell-based; the therapeutic window that distinguishes BAM15 from DNP has never been measured in a human.
- Mouse dosing was largely by diet admixture as a percentage of food weight, which does not translate to a human exposure and makes the effective dose in a person genuinely unknown.
- Uncoupling has no self-limiting feedback — the compound does not know when to stop — so margin-of-safety questions matter more here than for most metabolic mechanisms, and they are unanswered.
documented safety signals
- Class precedent: 2,4-dinitrophenol, the historical mitochondrial uncoupler, has 62 published fatalities documented in a 2011 Journal of Medical Toxicology review, with hyperthermia, tachycardia, diaphoresis and tachypnoea progressing to death, no specific antidote, and an average of roughly 14 hours from acute overdose to death.
- BAM15 is a chemically distinct molecule and rodent work reported no temperature effect up to 200 mg/kg with a wider in vitro window than DNP — but this distinction has never been confirmed in humans, so the class risk cannot be excluded, only argued against from animal data.
- No human adverse-event profile exists because no controlled human exposure has been published.
- Material sold to consumers is research-chemical supply, outside pharmaceutical identity and purity controls.
identity
| full name | BAM15 (mitochondrial protonophore uncoupler) |
| category | Metabolic |
| modality | small molecule |
| formula | C16H10F2N6O |
| molar mass | 340.3 g/mol |
| cas | 210302-17-3 |
laboratory handling
| storage | Vendor-specified for the research chemical: solid stored at -20 °C, protected from light. No approved pharmaceutical storage standard exists. |
| solubility | Poorly water-soluble. Cayman Chemical reports DMSO 20 mg/mL, DMF 20 mg/mL, ethanol 1 mg/mL, and DMSO:PBS pH 7.2 (1:5) 0.16 mg/mL. |
| co-studied with | No human combination data exists. Rodent work deliberately isolated BAM15 to show intake-independent effects; combining an uncoupler with any thermogenic or stimulant agent has no supporting evidence in any species and would compound the mechanism whose failure mode is hyperthermia. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
5 citedU.S. National Library of Medicine · 2026 · official
Cayman Chemical · 2026 · official
Nature Communications 2020;11:2397 · 2020 · preclinical
EMBO Molecular Medicine 2020;12:e12088 · 2020 · preclinical
Journal of Medical Toxicology 2011;7:205-212 · 2011 · reviews
others in Metabolic